Vice President
Vaxcyte
Vice President
Vaxcyte
Develops broad-spectrum vaccines for bacterial infections
The Vice President, Insights & Analytics (I&A) is a newly created role responsible for building Vaxcyte’s commercial insights, analytics, and forecasting capabilities, beginning with the U.S. adult launch of VAX-31. This leader will oversee the existing Market Research and Competitive Intelligence team while establishing new commercial analytics capabilities, bringing these functions together into an integrated organization that informs strategic and operational decision-making across the Commercial organization.
The VP, I&A will translate market research, customer insights, competitive intelligence, claims data, and commercial performance data into actionable insights that inform strategy, resource allocation, forecasting, and execution. As a trusted advisor to commercial and executive leadership, this role will provide a clear, integrated view of market dynamics, customer needs, competitive developments, and business performance to identify risks and opportunities and support confident, data-driven decisions.
This role sits within the Commercial organization and will partner closely with the Commercial Leadership Team, including the Launch Lead and leaders across Marketing, Sales, Market Access, and Digital Enablement, as well as Finance, Medical Affairs, and Scientific Affairs. The role will own the business questions, analytical priorities, interpretation, and communication of insights, while partnering with Digital Enablement, which owns the systems, platforms, and AI-enabled tools that support data access and analytical capabilities at scale.
Insights & Analytics Strategy and Organizational Leadership
Market Insights, Competitive Intelligence, and Forecasting
Commercial Analytics and Performance Management
Cross-Functional Partnership and Executive Advisory
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.
Explore more opportunities at Vaxcyte